Sensei Biotherapeutics (SNSE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SNSE Sensei Biotherapeutics

Watchlist

0.504
-0.009-1.75%

Trading Dec 4 14:04 ET

12.68MMarket Cap-423P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference
GlobeNewswireNov 27 16:05 ET
Sensei Biotherapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 14 08:06 ET · Announcements
Sensei Biotherapeutics Announces Organizational Restructuring and Progress on SNS-101 Clinical Trials With Data Expected in 2025
Quiver QuantitativeNov 14 07:48 ET
Sensei Biotherapeutics | 8-K: Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
SECNov 14 07:42 ET
Sensei Biotherapeutics Reports Q3 EPS (29c), Consensus (32c)
TipRanksNov 14 07:35 ET
Express News | Sensei Biotherapeutics Inc: Cash Runway Extended Into Q2 of 2026
ReutersNov 14 07:31 ET

Comments

Jaguar8

Oct 21 14:45

Hey 👋

$Sensei Biotherapeutics (SNSE.US)$

Sedliberanosamalo

May 24 09:07

Good news but price down

$Sensei Biotherapeutics (SNSE.US)$ anyone got any insights why? shoed FDA phase 1 approved.

Trytosaveabit

May 23 16:26

Here is the data I was waiting on!

$Sensei Biotherapeutics (SNSE.US)$ Sensei Biotherapeutics Inc: Reported Encouraging Clinical Data From Dose Escalation Portion of Its Phase 1/2 Trial of Sns-101
Once Every 3-Week Dosing of Sns-101 Demonstrates Initial Signs of Promising Clinical Activity
Pharmacokinetic and Safety Profile Validate Conditionally Active Approach in Study
Sensei Biotherapeutics Inc: Expects to Report Initial Data From Dose Expansion Cohorts and to Hold an End-of-Phase 1 Meeting With...

Trytosaveabit

May 14 04:56

Watching for data coming

$Sensei Biotherapeutics (SNSE.US)$ • There have been no dose limiting toxicities (DLT) observed across both the monotherapy and the combination arms.
• Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
• Title: Initial result...

Tom2808

May 2 13:04

$Sensei Biotherapeutics (SNSE.US)$ can we push pass 1.9 and go 2 onwards

Heat List

Overall

No Data